BioNTech to Acquire GMP Manufacturing Site: To Expand COVID-19 Vaccine Production Capacity in First Half 2021
BioNTech notes the transaction is expected to close in the fourth quarter of 2020. The Company plans to be able to produce up to 250 million doses of BNT162b2 in the first half of 2021.